Background: The paraventricular nucleus of the thalamus (PVT) is a limbic brain structure that affects ethanol (EtOH) drinking, but the neurochemicals transcribed in this nucleus that may participate in this behavior have yet to be fully characterized. The neuropeptide, pituitary adenylate cyclaseactivating polypeptide (PACAP), is known to be transcribed in other limbic areas and to be involved in many of the same behaviors as the PVT itself, possibly including EtOH drinking. It exists in 2 isoforms, PACAP-38 and PACAP-27, with the former expressed at higher levels in most brain regions. The purpose of this study was to characterize PACAP in the PVT and to assess its response to EtOH drinking.
T HE PARAVENTRICULAR NUCLEUS of the thalamus (PVT) is a limbic brain structure known to have an integral role in motivated behavior (Millan et al., 2017) and recently shown to participate specifically in ethanol (EtOH) drinking Dayas et al., 2008; Pandey et al., 2017) . Believed to contain glutamate as its primary classical neurotransmitter (identified by vesicular glutamate transporter 2 [vGLUT2]) (Frassoni et al., 1997; Moutsimilli et al., 2008) , the PVT has also been found to express several neuropeptides, specifically enkephalin, neurotensin, substance P, and corticotropin-releasing hormone (Arluison et al., 1994; Peng et al., 2017) , but it likely also contains others. This nucleus is considered to have 2 major subregions, the anterior PVT (aPVT) and posterior PVT (pPVT), which exhibit overlapping but distinct afferent and efferent connectivity (Li and Kirouac, 2008; Peng and Bentivoglio, 2004; Vertes and Hoover, 2008) and participate differentially in motivated behavior. For example, we have recently shown with microinjections of specific neuropeptides that activation of the aPVT promotes pharmacologically relevant EtOH drinking , while activation of the pPVT instead inhibits this drinking (Pandey et al., 2017) . Thus, the PVT subregions are differentially involved in EtOH intake, and this may be due to neurochemicals in the cells of the PVT itself, which have so far been incompletely characterized.
One neurochemical that may be located in the PVT is pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide structurally similar to vasoactive intestinal peptide, that has been identified in various limbic nuclei and, like the PVT itself, is implicated in a range of motivated and stress-related behaviors (Hsu et al., 2014; Miles et al., 2017; Shen et al., 2013) . Very limited evidence suggests that PACAP, like the PVT, may also be involved in EtOH drinking (Miyata et al., 1989; Tanaka et al., 2010) . While studies using immunoreactivity have yet to identify PACAP in cell bodies of the PVT, in situ hybridization studies examining the PACAP precursor (ADCYAP1) have detected PACAP mRNA in the pPVT, with the aPVT not examined (Murase et al., 1995; Skoglosa et al., 1999) . Studies also find PACAP to be particularly dense in the hypothalamus, including its PVN, as well as other limbic areas such as the amygdala, bed nucleus of the stria terminalis, and hippocampus (Hannibal, 2002; Murase et al., 1995) . In cultured C6 glioma cells, PACAP receptor levels are increased by EtOH exposure (He et al., 2002) , suggesting that PACAP itself may be responsive to EtOH intake, but this has not yet been investigated. Together, the literature suggests that PACAP could be responsive to EtOH exposure and may be located throughout the PVT, consistent with its expression in other limbic regions.
As there are 2 known isoforms of PACAP, it is possible that one or both are located in cells of the PVT. Originally isolated from the ovine hypothalamus, PACAP was initially identified as a 38-amino acid peptide (PACAP-38), which strongly stimulated 3'-5'-cyclic adenosine monophosphate (cAMP) accumulation in cultured rat anterior pituitary cells (Miyata et al., 1989) . Subsequently, a second PACAP isoform, corresponding to the N-terminal 27 residues of PACAP-38 (PACAP-27), was isolated and shown to induce cAMP accumulation at comparable levels (Miyata et al., 1990) . These isoforms are believed to be independently translated from ADCYAP1 (Miyata et al., 1990) , with PACAP-38 comprising the major portion of PACAP in the brain (Masuo et al., 1993) . Because of this, most studies involving PACAP have focused on PACAP-38.
The major goals of this study were 2-fold: first, to characterize the expression of PACAP in cells of the PVT; and second, to determine how PACAP in the PVT responds to EtOH. To accomplish this, we examined both gene and protein expression of PACAP throughout the rostrocaudal axis of the PVT, explored the neurotransmitter phenotype of the PACAPergic cells, and then investigated PACAP gene and protein expression following pharmacologically relevant EtOH drinking. We hypothesized that PACAP would be located throughout the PVT, with PACAP-38 as the principal isoform in this nucleus; that PACAP would be coexpressed with glutamate; and that PACAP levels would be altered following EtOH drinking, indicating that PACAP is involved in this motivated behavior.
MATERIALS AND METHODS

Subjects
Adult, male Sprague Dawley rats (N = 10; 8 weeks old; Charles River Laboratories International, Inc., Malvern, PA); adult male vGLUT2-GFP (green fluorescent protein) transgenic mice on a C57BL/6J background (N = 3; 8 weeks old; bred in-house from original mice generously donated by Dr. Ole Keihn) (Borgius et al., 2010 (Borgius et al., , 2014 Caldeira et al., 2017) ; and adult, male Long Evans rats (N = 28; 8 weeks old; Charles River Laboratories) were housed in an AAALAC-accredited facility, on a 12-hour light/dark cycle (lights off at 0900 hours for rats; lights on at 0700 hours for mice). They were given at least 1 week to acclimate to the facility, and rats were handled daily prior to the start of experiments. All animals received ad libitum chow (Laboratory Rodent Diet 5001; Lab Diet, St. Louis, MO) and water throughout the study. All rats were individually housed, to maintain consistent conditions across groups, matched with those required for EtOH-drinking groups. Mice were group housed, to minimize stress, as they were maintained in the facility for a longer duration. The strains and lines employed in this study were selected due to their common usage in alcohol research (Long Evans, Sprague Dawley, C57BL/6J), with the inclusion of these multiple models enabling broader conclusions to be drawn from consistencies or contradictions in the findings. Experiments were approved by the Institutional Animal Care and Use Committee of Drexel University College of Medicine and followed the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.
Experimental Protocols Experiment 1. To determine whether PACAP mRNA could be detected across the PVT, Sprague Dawley rats (N = 5) were sacrificed in the middle of the dark cycle via rapid decapitation to examine mRNA of PACAP in the anterior/middle PVT (a/mPVT) and middle/posterior PVT (m/pPVT) using quantitative real-time polymerase chain reaction (qPCR). Food was removed 60 minutes prior to sacrifice. Experiment 2. To identify the PACAP isoform(s) present in cell bodies of the PVT subregions, Sprague Dawley rats (N = 5) were anesthetized and perfused in the middle of the dark cycle for analysis using immunofluorescent histochemistry of PACAP-27, PACAP-38, and the nuclear stain 4',6-diamidino-2-phenylindole (DAPI). To confirm the presence of PACAP protein in PVT cells using a different antibody, thus enhancing scientific rigor, alternate brain slices were used for analysis using immunofluorescent histochemistry with an antibody that labels both PACAP isoforms. Food was removed 60 minutes prior to sacrifice. Experiment 3. To establish that PACAP colocalizes with the primary classical neurotransmitter of the PVT, glutamate, vGLUT2-GFP mice (N = 3) were anesthetized and perfused at the end of the light cycle for analysis using immunofluorescent histochemistry of PACAP-27, vGLUT2, and DAPI. Experiment 4. To determine whether levels of PACAP mRNA are affected by pharmacologically relevant EtOH drinking, Long Evans rats were trained to drink 20% EtOH under the intermittentaccess 2-bottle choice paradigm or were maintained on water and chow only (n = 8/group). During the fifth week of training, starting 45 minutes into daily access and with food removed 60 minutes prior, they were sacrificed via rapid decapitation to examine mRNA of PACAP in the a/mPVT and m/pPVT using qPCR. We have previously shown that Long Evans rats drinking under this model have stable EtOH intake by week 4 of training and that their peak intake occurs during the first 30 minutes of daily EtOH access (Pandey et al., 2017) .
Experiment 5. To confirm that PACAP protein is also affected by pharmacologically relevant EtOH drinking, Long Evans rats were trained to drink 20% EtOH or were maintained on water and chow only (n = 6/group). During the fifth week of training, starting 100 minutes into daily access and with food removed 60 minutes prior, they were perfused for analysis using immunofluorescent histochemistry of PACAP-27, PACAP-38, and DAPI.
EtOH Drinking
Rats trained to drink EtOH drank unsweetened 20% v/v EtOH under the intermittent-access 2-bottle choice paradigm adapted from Wise (1973) and Simms and colleagues (2008) , which involved access to EtOH during three 24-hour sessions per week in addition to ad libitum water and chow. One hour after dark onset, 1 of their two 16 oz Makrolon bottles of water (Ancare, Bellmore, NY) was replaced with a 9 oz polycarbonate bottle of EtOH (Ancare), and after 24 hours, the EtOH was replaced with the second bottle of water. This was repeated each Monday, Wednesday, and Friday for a total of 13 complete sessions. Relative bottle position was alternated at each session to prevent side preference, and all bottles were fitted with nondrip sipper tubes of equal size. Animals were weighed on Tuesdays and Saturdays. To determine blood EtOH concentration (BEC), trunk blood was obtained from the group tested for qPCR (Experiment 4), which was sacrificed 45 minutes after the start of daily EtOH access. The blood was then centrifuged, and plasma was extracted and tested using an Analox AM1 Alcohol Analyzer (Lunenburg, MA). Rats used as water controls were treated identically except that their 2 bottles always contained water.
Quantitative Real-Time PCR
Dissections of the a/mPVT, m/pPVT, and PVN were taken for analysis with qPCR. The middle PVT (mPVT) was bisected and grouped with the aPVT and pPVT, as finer division of the subregions was not possible for these experiments. Immediately after sacrifice, the brain was placed with the ventral surface facing up in a matrix slicing guide set on ice. Three coronal cuts were made, starting with the middle optic chiasm (bregma À1.5 mm) (Paxinos and Watson, 2005) . The second cut was 1.0 mm caudal to this, yielding a slice (bregma À1.5 to À2.5 mm) for microdissection of the a/ mPVT and PVN, and the third cut was 1.0 mm caudal to that, yielding a slice (bregma À2.5 to À3.5 mm) for the m/pPVT. Under a microscope, on a slide placed on a petri dish filled with ice, the a/ mPVT and m/pPVT were dissected as inverted isosceles triangles directly ventral to the dorsal third ventricle, approximately 0.8 mm wide at the base, while the PVN was dissected as an inverted isosceles triangle, 1.0 mm bilateral to the third ventricle and between the fornix structures. The sections were stored at À20°C in RNAlater (Qiagen Inc., Valencia, CA) until extraction of RNA.
As previously described (Pandey et al., 2017) , total RNA from each brain section was purified using the RNeasy Mini Kit (Qiagen Inc.) and DNA was removed using RNase-free DNase 1 (Qiagen Inc.). The yield was quantified with a NanoDrop Lite Spectrophotometer (Thermo Electron North America LLC, Madison WI), with resulting A 260 /A 280 ratios between 2.00 and 2.26, indicating high purity. cDNA was reverse-transcribed using SuperScript Ò VILO TM Master Mix (Invitrogen, Grand Island, NY) in a SimpliAmp TM Thermal Cycler (Applied Biosystems, Waltham, MA), using 1 lg of RNA from each sample. Minus RT controls were synthesized by denaturing the reverse transcriptase. For qPCR the SYBR Green PCR Core Reagents Kit (Applied Biosystems, Grand Island, NY) was used in MicroAmp Ò Fast Optical 96-Well Reaction Plates (Applied Biosystems), with 12.5 ng of cDNA template in a 25 ll reaction volume. The reaction was carried out on a StepOnePlus Real-Time PCR System (Applied Biosystems), under the conditions of 2 minutes at 50°C, 10 minutes at 95°C, 40 cycles of 15 seconds at 95°C, and 1 minute at 60°C. Each sample was run in triplicate, and each run included a no-template and minus RT control. Target gene expression was quantified relative to cyclophilin-A using the relative quantification method (DDC T ). Primers were designed with the NCBI primer design tool (http://www.ncbi.nlm.nih.gov/tools/prime r-blast/) (Ye et al., 2012) and purchased from Invitrogen at ThermoFisher Scientific (Grand Island, NY). The primers, used at a 200 nM concentration, were cyclophilin-A forward: 5 0 -GTGTTCT TCGACATCACGGCT-3 0 , reverse: 5 0 -CTGTCTTTGGAACTTT GTCTGCA-3 0 ; and PACAP forward: 5 0 -GCCTCTCTGGTTGT GATTCCA-3 0 , reverse: 5 0 -GGTCATTCGCGGCTAGGAA-3 0 .
Immunohistochemistry
Rats were deeply anesthetized with 75 mg/kg ketamine (Fort Dodge Animal Health, Overland Park, KS) and 10 mg/kg xylazine (LLOYD Incorporated, Shenandoah, IA) (intraperitoneal [i.p.]) and perfused transcardially with 60 ml of ice-cold 0.9% sodium chloride followed by 240 ml of 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Mice were deeply anesthetized with 150 mg/kg ketamine and 10 mg/kg xylazine (i.p.) and perfused transcardially with 30 ml of ice-cold 0.9% sodium chloride followed by 50 ml of 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Brains were then removed, postfixed in 4% paraformaldehyde for 24 hours at 4°C, transferred to 30% sucrose for 2 to 4 days at 4°C, and then frozen at À80°C. They were sliced coronally on a cryostat at 30 lm, and the sections were stored at À20°C in antifreeze solution (37.5% ethylene glycol, 20% sucrose in 0.03 M phosphate-buffered saline [PBS] ). Free-floating sections were processed for immunohistochemistry to label PACAP. Every sixth section through the PVT was taken for analysis, resulting in approximately 18 sections per brain/analysis for rats and 10 sections per brain/analysis for mice. Serial sections were taken for distinct analyses.
To label PACAP-27 and PACAP-38, sections were rinsed for 10 minutes in 0.1% hydrogen peroxide to remove endogenous peroxidase activity. After rinsing in 0.1 M PBS, they were blocked for 90 minutes in 5% normal goat serum containing 0.5% Triton X-100 in PBS and incubated overnight at 4°C in polyclonal guinea pig anti-PACAP-27 antibody (1:250; Peninsula Laboratories International, Inc., San Carlos, CA; cat# T-5039.0050, lot# 040119-1) and, for rat tissue, also polyclonal rabbit anti-PACAP-38 antibody (1:250; Peninsula Laboratories International, Inc. cat# T-4473.0050, lot# A14722 and A16369). The specificity of these antibodies has previously been validated using both immunohistochemistry and Western blot (Ahnaou et al., 2006; Koh et al., 2003; Moore et al., 2012) . After this, the slices were rinsed in PBS and then incubated for 2 hours in goat anti-guinea pig (Alexa Fluor Ò 555) (1:200; Abcam, Cambridge, MA; cat# ab150186, lot# GR128511-1) and goat anti-rabbit (Alexa Fluor Ò 488) (1:200; Abcam; cat# ab150077, lot# GR239034-1) secondary antibodies in block solution. Pilot experiments were run to determine optimal staining conditions. Alternate sections did not show immunofluorescence when processed with the primary or secondary antibody omitted. Sections were mounted on slides and dried overnight in the dark, coverslipped with ProLong Ò Diamond Antifade Mountant with DAPI (Life Technologies, Carlsbad, CA) and allowed to set for 24 hours prior to imaging.
To label both PACAP isoforms with a single antibody, sections were initially processed as above, instead using 10% normal donkey serum for block solution. They were then incubated for 40 hours at 4°C in polyclonal rabbit anti-PACAP antibody (1:50; Abcam; cat# ab174982, lot# GR138714-12) in block solution. After this, the slices were rinsed with PBS and incubated for 90 minutes with biotinylated donkey anti-rabbit secondary antiserum (1:500; Vector Laboratories, Burlingame, CA) in block solution. Sections were then incubated with avidin-biotin-horseradish peroxidase complex (1:300; Vectastain Elite ABC Kit; Vector Laboratories) in PBS for 60 minutes. After rinses with PBS, the tissue was reacted with 3,3 0 -diaminobenzidine tetrahydrochloride (DAB) as a chromogen. After additional rinses with dH 2 O and then PBS, the sections were mounted on slides (Fisherbrand Superfrost Plus; ThermoFisher Scientific, Pittsburgh, PA) and dried overnight. They were then dehydrated with a graded EtOH ladder, cleared with Shandon Xylene Substitute (ThermoFisher Scientific), and coverslipped with Permount mounting medium (ThermoFisher Scientific). Immunofluorescent brain slices were imaged for analysis with a Leica DM5500 automated microscope (Buffalo Grove, IL), and the images were captured with an Olympus DP71 high-resolution digital color camera (Waltham, MA) with Slidebook V6 image acquisition and analysis software (3i, Denver, CO). These analyses were confirmed with a Leica SP8 VIS/405 HyVolution confocal microscope. Brain slices processed with DAB were imaged for analysis with a Zeiss Axio Lab.A1 microscope, and the images were captured with an Axiocam and ZEN software (Carl Zeiss Microscopy, LLC, Thornwood, NY). Exposure conditions were the same for each slice processed with each primary antibody. Due to the anatomical precision of this technique, sections could be defined as aPVT (À0.84 to À2.04 mm for rat; À0.22 to À0.93 mm for mouse), mPVT (À2.05 mm to À2.99 mm for rat; À0.94 to À2.17 mm for mouse), or pPVT (À3.00 to À4.08 mm for rat; À2.18 to À2.45 mm for mouse) relative to bregma (Paxinos and Franklin, 2004; Paxinos and Watson, 2005) . Staining was quantified by an evaluator blind to group membership. Cells stained with PACAP-27, PACAP-38, and vGLUT2 were counted manually. Cells single-labeled with DAPI or DAB were counted using NIH software, ImageJ version 1.48v for Windows (Schneider et al., 2012) . To do this, the image in the appropriate channel was converted to grayscale, the PVT was isolated and the threshold adjusted, with the same limits used for each slice/antibody, and software counts were initially matched to manual counts. The average number of labeled cells per slice for each antibody was determined for each subregion. To measure integrated density for PACAP-27 and PACAP-38, the image in the appropriate channel was converted to grayscale in ImageJ, the PVT was isolated, and the measure function was employed. Integrated density evaluates all fluorescence, both cell bodies and fibers. To measure PACAP-27 cell fluorescence intensity, the integrated density of individual cells was measured in ImageJ and the mean fluorescence of background readings, multiplied by the area of the selected cell, was subtracted from this cell integrated density measurement. This was repeated for 20 cells at the same level in each subregion of each animal, and the average number of labeled cells was determined for each subregion.
Data Analysis
Differences between 2 PVT subregions were analyzed by pairedsamples t-tests with 2 tails. Comparisons between groups were made using independent-samples t-tests with 2 tails. To examine specific antibody labeling, a 1-way analysis of variance (ANOVA) was used. To examine labeling of PACAP, a repeated-measures or mixed ANOVA was used, with subregion and isoform as the repeated measures and drinking group as the between-subjects measure, where appropriate. Significant main effects were followed up with a Sidak pairwise comparison test, and significant interaction effects were followed up with additional 1-way or mixed ANOVAs (with PVT subregion as the repeated measure and drinking group as the between-subjects measure) and a Sidak pairwise comparison test where appropriate. Linear regression was used to examine the relationship between EtOH intake and BEC and cell fluorescence intensity. Significance was determined at p < 0.05. Data are reported as mean AE standard error of the mean (SEM).
RESULTS
Experiment 1: Gene Expression of PACAP in the PVT
To examine PACAP mRNA across the PVT, the a/mPVT and m/pPVT from rats (N = 5) were analyzed using qPCR. Comparing gene expression between the subregions, a significant difference was detected [t(4) = À3.20, p < 0.05], with levels of PACAP mRNA being higher in the m/pPVT than in the a/mPVT (Fig. 1) . Thus, PACAP mRNA is detectable across the PVT but is denser in the posterior portion of the PVT.
Experiment 2: Protein Expression of PACAP-27 and PACAP-38 in the PVT To characterize PACAP protein in the PVT, rats (N = 5) were examined using immunofluorescent histochemistry with validated antibodies to label PACAP-27, PACAP-38, and cellular nuclei (DAPI) in the aPVT, mPVT, and pPVT. Comparing the overall density of labeling of the PACAP isoforms across subregions, the analysis revealed no significant main effect of isoform [F(1, 4) = 2.47, not significant (ns)] or subregion [F(2, 8) = 1.17, ns], indicating that overall PACAP labeling in the PVT was similar between PACAP-38 and PACAP-27 and across the aPVT, mPVT, and pPVT.
Notably, while PACAP-38 was primarily located in fibers in the PVT, PACAP-27 was primarily detected in soma of the PVT; thus, the PACAP isoforms were additionally analyzed by counting immunopositive cells. In examining general cellular nuclei across the PVT subregions, there were no significant main effects for the average number of DAPI Fig. 2A,B) . Specifically, there was a significant main effect for PACAP isoform [F(1, 4) = 912.18, p < 0.001], with greater colabeling of DAPI + with PACAP-27 compared to PACAP-38 (44% vs. 10%). Notably, cells containing PACAP-38 always colabeled with PACAP-27. There was also a trend for a significant main effect for PVT subregion [F(2, 8) = 3.79, p = 0.07], with pairwise comparisons revealing that the mPVT had more overall PACAP colabeling than the aPVT (p < 0.05). Finally, there was also a significant interaction effect between PACAP isoform and PVT subregion [F(2, 8) = 7.08, p < 0.05]. Follow-up of this effect, first through examination of specific colabeling of DAPI with PACAP-27, revealed that there was again a significant main effect of subregion [F(2, 8) = 5.00, p < 0.05], with pairwise comparisons showing that this was due to significantly more PACAP-27 colabeling in the mPVT compared to the aPVT (47% vs. 37%, p < 0.05). Although it did not attain statistical significance, there was also more colabeling in the pPVT compared to the aPVT (48% vs. 37%). Examination of specific colabeling of DAPI with PACAP-38, in contrast, revealed that there was no significant difference across subregions [F(2, 8) = 1.09, ns]. These results focus attention on PACAP-27 as being present in a high percentage of cell bodies of the PVT, particularly in the mPVT and pPVT, and suggest that PACAP mRNA in the PVT may be primarily translated into PACAP-27.
To confirm the identification of PACAP in soma of the PVT, alternate slices from the same rats (N = 5) were examined immunohistochemically using an antibody that targeted both PACAP-27 and PACAP-38 (Fig. 3A,B) . This antibody again labeled numerous cells in the PVT. Analyzing the number of PACAP + cells, a significant main effect was found for PVT subregion [F(2, 8) = 7.54, p < 0.05], with pairwise comparisons revealing that this was due to significantly greater labeling in the pPVT compared to the aPVT (p < 0.05). These results with an additional antibody strongly support the idea that PACAP is densely expressed in cell bodies of the PVT, particularly in the posterior portion of the PVT.
Experiment 3: Colocalization of PACAP-27 and Glutamate in the PVT
To assess the neurotransmitter phenotype of the PACAP-27 + cells in the PVT, determining whether they are colocalized with the major classical neurotransmitter of the PVT, immunohistochemistry was used on tissue from vGLUT2-GFP mice (N = 3) to examine PACAP-27, vGLUT2, and DAPI in the aPVT, mPVT, and pPVT. Consistent with the findings in rats, nearly half of all DAPI + cells colabeled with PACAP-27, although this percentage was fairly uniform across all 3 PVT subregions (43 to 47%) (Table 1) . Notably, every PACAP-27 + cell colabeled with vGLUT2. Moreover, the percentage of DAPI + cells that colabeled with vGLUT2 was very high, ranging from 75 to 78% across the PVT (Table 1) . Despite this dense glutamatergic labeling, more than half of all vGLUT2 + cells in the PVT colabeled with PACAP-27 (57 to 60%) (Table 1 and Fig. 4 ). These results demonstrate that PACAPergic cells in the PVT are glutamatergic and that, across all subregions of the PVT, the majority of cells contain glutamate.
Experiment 4: Response of PACAP Gene Expression in the PVT to EtOH Drinking
Having established that PACAP is present throughout the PVT, the next step was to determine whether levels of PACAP mRNA in the PVT are affected by EtOH drinking. Rats were trained to drink 20% EtOH using the intermittent-access model or were maintained on water and chow only (n = 8/group), and gene expression was then examined using qPCR. Rats with access to EtOH drank an average of 5.4 AE 0.9 g/kg/d. On the day of sacrifice, they consumed 1.4 AE 0.3 g/kg EtOH in 45 minutes and achieved BECs of 59 AE 14 mg/dl, which were significantly predicted by their 45-minute EtOH intake (R 2 = +0.81, p < 0.01). Starting by examining levels of PACAP mRNA in the PVT, a main effect was found for subregion [F(1, 14) = 25.25, p < 0.001], with gene expression being higher overall in the m/pPVT than in the a/mPVT, as in Experiment 1. Turning to the effect of EtOH drinking on levels of PACAP mRNA in the PVT, there was a strong trend for a main effect of drinking condition [F(1, 14) = 4.02, p = 0.07], with EtOH stimulating PACAP expression by 42% in the a/mPVT and 88% in the m/pPVT (Fig. 5) . In comparison, in another brain region where PACAP is heavily expressed, the PVN in the hypothalamus, there was no effect of EtOH drinking [t(14) = 0.13, ns]. Thus, EtOH intake appears to stimulate gene expression of PACAP and this effect is anatomically specific, occurring in the PVT but not the PVN.
Experiment 5: Response of PACAP-27 and PACAP-38 Protein Expression in the PVT to EtOH Drinking
To ascertain whether EtOH drinking preferentially affects a specific isoform of PACAP, a second group of rats was trained to drink 20% EtOH using the intermittent-access model or was maintained on water and chow only (n = 6/ group). Immunohistochemistry was then used to examine PACAP-27, PACAP-38, and DAPI. Rats with access to EtOH drank an average of 4.1 AE 0.6 g/kg/d. On the day of sacrifice, they consumed 1.5 AE 0.2 g/kg EtOH in 100 minutes. Looking first at the percentage of DAPI + cells that colabeled with PACAP, there were no main effects of drinking condition on colabeling with PACAP-27 [F(1, 10) = 0.03, ns] or PACAP-38 [F(1, 10) = 1.57, ns], suggesting that the number of PACAP + cells was not affected by EtOH. Moreover, there was no significant effect of EtOH drinking on the density of labeling of PACAP-38 [F(1, 10) = 2.53, ns] which, as before, was found primarily in fibers (Fig. 6A) . PVT (Fig. 6A) , it was notable that PACAP-27 labeling was increased by 29% in the pPVT, compared to 15% in the aPVT and 18% in the mPVT. This increased labeling of PACAP-27 in the PVT was additionally observed as a greater level of fluorescence in individual PACAP-27 + cells in the PVT of EtOH compared to water drinkers [F(1, 10) = 5.95, p < 0.05], with a lack of interaction between drinking condition and PVT subregion [F(2, 20) = 2.50, ns] again indicating that the increase occurred across the PVT (Fig. 6B,C) . Notably, among EtOH drinkers, average cell fluorescence intensity for PACAP-27 was very strongly predicted by average level of daily drinking (g/kg/d) (R 2 = +0.93, p < 0.01). Thus, EtOH drinking specifically increases levels of PACAP-27 in individual cells of the PVT, increasing PACAP protein in cells that already produce this neuropeptide.
DISCUSSION
The results of this study identify a neuropeptide that is densely expressed in the PVT and is responsive to EtOH drinking. Specifically, they show that PACAP is present throughout the rostrocaudal extent of the PVT in both rats and mice. In addition, the less ubiquitous of its isoforms, PACAP-27, is expressed in nearly half of all PVT cells, is particularly dense in the posterior portion of the PVT, and is contained in glutamatergic cells. Importantly, the results show that levels of PACAP-27 in cells of the PVT are increased following pharmacologically relevant EtOH drinking. These results focus attention on changes in PACAP-27 in the PVT as a novel consequence of EtOH drinking.
Our results show that PACAP is dense in both cell bodies and fibers throughout the PVT subregions. This was demonstrated with both qPCR and immunohistochemistry, using well-validated antibodies directed against the specific PACAP isoforms as well as 1 directed antibody against both PACAP isoforms. Previous research using in situ hybridization identified PACAP mRNA in the pPVT, but did not examine the aPVT (Murase et al., 1995; Skoglosa et al., 1999) , and immunohistochemical research using a different antibody believed to be directed against both isoforms Quantification of cells expressing pituitary adenylate cyclase-activating polypeptide-27 (PACAP-27), vesicular glutamate transporter 2 (vGLUT2), and 4',6-diamidino-2-phenylindole (DAPI) in the overall paraventricular nucleus of the thalamus (PVT), as well as the anterior PVT (aPVT), middle PVT (mPVT), and posterior PVT (pPVT) of vGLUT2-GFP transgenic mice (N = 3), using immunofluorescent histochemistry (Experiment 3). Values are mean AE SEM. Shaded area represents values for individual PVT subregions. Fig. 4 . Confocal photomicrograph showing cells expressing pituitary adenylate cyclase-activating polypeptide-27 (PACAP-27; red), vesicular glutamate transporter 2 (vGLUT2; green), and 4',6-diamidino-2-phenylindole (DAPI; blue) in the paraventricular nucleus of the thalamus (PVT) of male vGLUT2-GFP transgenic mice (Experiment 3). Inset is a higher magnification of the image marked with a white square. Scale bars = 100 lm in main image and 30 lm in inset. reported that PACAP protein was dense only in fibers of the PVT (Hannibal, 2002; Koves et al., 1991) . These latter results are difficult to interpret, as they did not specify the rostrocaudal level or number of sections examined, and thus may have sampled only the aPVT, where PACAP expression is lower. By examining serial sections throughout the entire PVT and using several different antibodies, we demonstrate here that PACAP is not only dense in fibers as reported (Hannibal, 2002; Koves et al., 1991) , but is also expressed in nearly half of all PVT cells. This is consistent with the presence of PACAP in soma of other limbic regions (Koves et al., 1991; Masuo et al., 1993) , suggesting that the PVT shares this neurochemical feature with its larger brain network.
A central finding of the present experiments is the identification of PACAP-27 as the major PACAP isoform in cell bodies of the PVT. This is in contrast with much of the rest of the brain, where PACAP-38 comprises the major portion of total PACAP protein (Masuo et al., 1993) and is more frequently examined in studies of behavioral function. The limited literature on PACAP-27 suggests that it regulates feeding behavior and the sympathetic response (Mungan et al., 1992; Nandha et al., 1991; Vu et al., 2015) , both of which are also affected by the PVT (Huang et al., 1988; Millan et al., 2017) . It should be noted that, while the majority of PACAP-27 + cells in the PVT may be neurons, PACAP has also been identified in glia (Hirose et al., 2005; Van Landeghem et al., 2007) , so future research should determine which specific cell types in the PVT contain PACAP-27. Our discovery of the less ubiquitous PACAP isoform in the PVT is perhaps not unexpected in light of evidence that it is also present in cell bodies of some other regions of the limbic system, including the supraoptic nucleus and the PVN in the hypothalamus, as well as the periaqueductal gray (Kivipelto et al., 1992) , and PACAP-27 binding has been found to be dense in the PVT itself (Masuo et al., 1992) . In line with this finding that the PVT is one of a restricted number of brain areas containing PACAP-27 + cells, this nucleus also demonstrates other neurochemical traits that differentiate it from other brain regions. For example, while the orexin-/hypocretin-induced promotion of excessive substance intake occurs primarily via the orexin 1 receptor in most of the limbic system, it occurs primarily via the orexin 2 receptor in the PVT . Thus, while the PVT shares a number of traits with other limbic regions, it also exhibits its own, distinguishing characteristics.
In characterizing the neurotransmitter phenotype of the PACAPergic cells of the PVT, we found that they are glutamatergic and that glutamate is in fact contained in more than 75% of all cells in the PVT. While it has been noted in multiple studies that vGLUT2 exists at high levels in neurons of the PVT (Moutsimilli et al., 2008; Zhang and Van Den Pol, 2017) , our results provide the first direct evidence that a much higher percentage of PVT neurons contain glutamate than the 30% estimated by an earlier study using an older antiglutamate antibody (Frassoni et al., 1997) . As with PACAP, it is possible that vGLUT2 is present not only in neurons but also in glia (Danik et al., 2005; Li et al., 2013 ). While we used in the present study the general nuclear stain, DAPI, which does not allow us to distinguish between these cell types, we expect, based on research suggesting that the glia-to-neuron ratio in the PVT is about 1-to-1 (Bandeira et al., 2009) , that most neurons in the PVT express glutamate and a significant portion of glutamatergic neurons coexpress PACAP-27. Importantly, our results show for the first time that levels of PACAP in the PVT are increased by pharmacologically relevant EtOH drinking. This occurs in an anatomically specific manner, in the PVT but not in the PVN, and in an isoform-specific manner, for PACAP-27 but not for PACAP-38. Moreover, this increase occurs within PACAP-27 + soma, confirming that it is affecting the cells of the PVT itself. It is also directly related to the amount of EtOH consumed over several weeks of access. Prior research connecting EtOH with PACAP has shown in cultured C6 glioma cells that acute EtOH exposure increases gene expression of the PACAP receptor (He et al., 2002) , suggesting that EtOH affects PACAP release, in addition to expression. Future research should determine whether the changes observed in the present study also occur in response to EtOH under other conditions, such as after experimenter-administered EtOH, with dependence, and in females. Gene expression of PACAP in the limbic system has also been found to be upregulated by other, related circumstances. Specifically, PACAP in the bed nucleus of the stria terminalis is increased by self-administration of cocaine, and also by chronic variable stress (Hammack et al., 2009; Miles et al., 2017) . In turn, there is evidence that PACAP-27 may provide a negative feedback signal to curb EtOH intake. Compared to wild-type mice, PACAP knockout mice have a significantly greater preference for EtOH and increased EtOH-induced conditioned place preference (Tanaka et al., 2010) , indicating that endogenous PACAP suppresses EtOH intake and reward. The present findings also have clinical relevance, as suggested by evidence that polymorphisms of the PACAP receptor in humans are associated with problematic alcohol use (Dragan et al., 2017; Kovanen et al., 2010) . Therefore, in response to EtOH drinking, the rise in levels of PACAP-27 in cells of the PVT could represent a homeostatic mechanism for regulating intake.
Given their divergent anatomical connections and roles in behavior, it is notable that the posterior compared to the anterior portion of the PVT in rats showed heavier expression of PACAP and a slightly greater increase in levels of PACAP-27 in response to EtOH drinking. Given our recent finding that neuropeptide-induced activation of the pPVT inhibits EtOH drinking (Pandey et al., 2017) , this lends further support to the idea that PACAP-27 could curb EtOH intake. We propose that PACAP release from the PVT subregions may also contribute to their other known effects, particularly in the case of the pPVT. For example, compared with the aPVT, the pPVT sends denser anatomical projections to the bed nucleus of the stria terminalis (Li and Kirouac, 2008) and is more strongly linked with the stress response Bhatnagar et al., 2003; Li et al., 2010) and drug-seeking behavior (Matzeu et al., 2016) . Notably, the bed nucleus of the stria terminalis is known to receive dense PACAPergic afferent fibers (Kozicz et al., 1997) and PACAP here is found to increase anxiety-like behavior and promote drug seeking, much like the pPVT itself (Hammack et al., 2009; Miles et al., 2017) . In contrast to the pPVT, the aPVT sends denser anatomical projections to the suprachiasmatic nucleus (Moga et al., 1995) and is more strongly linked with control of the circadian system (Yan and Silver, 2016) . In fact, extracellular PACAP in the suprachiasmatic nucleus is known to control circadian rhythms (Michel et al., 2006) . Taken together, the published literature suggests that the roles of the PVT subregions in behavior may occur, in part, through their release of PACAP, with this PVT neuropeptide perhaps making a greater contribution to stress-, alcohol-, and drug-related behavior due to its heavier expression in the pPVT than the aPVT.
Together, our results identify the involvement of the peptide, PACAP-27, in pharmacologically relevant EtOH drinking. They show that it is densely expressed in cells of the PVT, an area of the brain recently found to participate in this behavior Pandey et al., 2017) . Adding to clinical evidence implicating the PACAP receptor in EtOH drinking, our findings, showing anatomically specific effects of this selectively expressed PACAP isoform, indicate that PACAP-27 should be further investigated for its role in EtOH drinking.
ACKNOWLEDGMENTS
This research was supported by the National Institute on Alcohol Abuse and Alcoholism under Award Number R00AA021782 (JRB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors have no conflict of interest to declare. We would like to thank Dr. Ole Keihn and Charlotta Borgius at the Karolinska Institutet for providing the original vGLUT2-GFP mice and Dr. Kimberly Dougherty and Lihua Yao at Drexel University College of Medicine for providing the specific vGLUT2-GFP mice used in this work. We thank Priyanka Shah for assistance in the analysis of the vGLUT2-GFP immunohistochemistry.
